THROMBOSIS AND HEMOSTASIS Proteolytic antibodies activate factor IX in patients with acquired hemophilia
نویسندگان
چکیده
1Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris, France; 2Université Paris Descartes, Unité Mixte de Recherche S872, Paris, France; 3Inserm, U872, Paris, France; 4Inserm U770 and Université Paris-Sud, Le Kremlin-Bicêtre, France; 5Inserm, U698, Université Paris 7, Paris, France; 6Université de Technologie de Compiègne, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 6022, Génie Enzymatique et Cellulaire, Compiègne Cedex, France; 7Laboratoire d’Hématologie, Université de Caen, Caen, France; 8Rouen University Hospital, Rouen, France; and 9Unité Mixte de Recherche S943, Paris, France
منابع مشابه
Rituximab for Treatment of Hemophilia A with High-Responder Inhibitors
Background: The development of inhibitors is a complication factor replacement therapy in hereditary factor VIII deficiency. Several management options are available for the treatment of inhibitor. Rituximab, a monoclonal antibody against CD20, reduces inhibitor level in rare bleeding disorders. The aim of this study was to evaluate the effectiveness of rituximab in lowering or eliminating the ...
متن کاملHEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Creation of a mouse expressing defective human factor IX
The majority of cases of human hemophilia B are the result of missense mutations in the coagulation factor IX gene and defective circulating factor IX is detectable in most patients. The available mouse factor IX knockout models of hemophilia B (FIXKO mouse) reproduce the bleeding phenotype of human hemophilia B, but because the models produce no factor IX they fail to reproduce the dominant hu...
متن کاملFactor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo.
We have infused recombinant factor VIIa into patients with hereditary factor VII deficiency with marked reductions in plasma concentrations of factor IX activation peptide (FIXP), factor X activation peptide (FXP), and prothrombin activation fragment F1+2. These investigations show substantial elevations in these markers of coagulation activation and thereby demonstrate that the factor VII-tiss...
متن کاملHEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Mechanism of factor VIIa–dependent coagulation in hemophilia blood
The ability of factor VIIa to initiate thrombin generation and clot formation in blood from healthy donors, blood from patients with hemophilia A, and in anti–factor IX antibody–induced (“acquired”) hemophilia B blood was investigated. In normal blood, both factor VIIa–tissue factor (TF) complex and factor VIIa alone initiated thrombin generation. The efficiency of factor VIIa was about 0.0001 ...
متن کاملHEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis
The role of the factor IXa heparin-binding exosite in coagulation was assessed with mutations that enhance (R170A) or reduce (R233A) stability of the proteasefactor VIIIa A2 domain interaction. After tissue factor (TF) addition to reconstituted factor IX-deficient plasma, factor IX R170A supported a 2-fold increase in velocity index (slope) and peak thrombin concentration, whereas factor IX R23...
متن کامل